ClinicalTrials.Veeva

Menu

Quality of Life and Participation of the Adult with Spinal Muscular Atrophy in France (QOLSMA)

Civil Hospices of Lyon logo

Civil Hospices of Lyon

Status

Completed

Conditions

Spinal Muscular Atrophy

Treatments

Other: SMA adult patients

Study type

Observational

Funder types

Other

Identifiers

NCT05366465
69HCL22_0200

Details and patient eligibility

About

Spinal muscular atrophy is a hereditary motorneuron disease caused by a mutation of the SMN1 gene, which is at the origin of a progressive limb and axial motor deficiency. It concerns 1200 individuals in France, including 700 adults in 2018. The main objective of this study is to assess the quality of life of SMA patients in France.

The secondary objectives are, in one hand, to compare the quality of life of SMA patients to a population of neuromuscular diseases patients. And on the other hand to evaluate the determinants of participation and the impact of participation on quality of life in adult SMA patients.

Enrollment

149 patients

Sex

All

Ages

18 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patient with SMA type 1, 2, 3 or 4
  • ≥ 18 years old
  • giving informed consent to participate to the study
  • patients from the study of Dany et al "Construction of a Quality of Life Questionnaire for slowly progressive neuromuscular disease" (2015)

Exclusion criteria

  • patients who do not complete ≥ 80% of the questionnaire)-

Trial design

149 participants in 1 patient group

SMA adult patients
Treatment:
Other: SMA adult patients

Trial contacts and locations

2

Loading...

Central trial contact

RIBAULT Shams; VUILLEROT Carole, Pr

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems